Guangdong Jiaying Pharmaceutical Co., Ltd (SHE:002198)
China · Delayed Price · Currency is CNY 3.820
-0.060 (-1.55%)
Sep 8, 2026, 3:04 PM CST
SHE:002198 Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 4, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
| 1,929 | 3,568 | 3,715 | 3,695 | 3,309 | 3,999 | |
Market Cap Growth | -40.34% | -3.96% | 0.55% | 11.66% | -17.26% | 75.89% |
Enterprise Value | 1,820 | 3,440 | 3,418 | 3,409 | 3,102 | 3,818 |
Last Close Price | 3.88 | 7.03 | 7.32 | 7.23 | 6.47 | 7.82 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 4, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
PE Ratio | - | 117.06 | 180.24 | 107.65 | 75.32 | 2707.14 |
Forward PE | - | 21.70 | 21.70 | 21.70 | 21.70 | 21.70 |
PS Ratio | 5.50 | 9.30 | 9.88 | 6.93 | 5.02 | 6.96 |
PB Ratio | 2.74 | 4.97 | 4.90 | 4.84 | 4.54 | 5.84 |
P/TBV Ratio | 2.94 | 5.31 | 5.22 | 5.16 | 4.89 | 6.39 |
P/FCF Ratio | - | - | 167.76 | 39.56 | 135.53 | 80.86 |
P/OCF Ratio | - | 396.33 | 61.05 | 37.53 | 121.86 | 77.20 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 4, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
EV/Sales Ratio | 5.19 | 8.96 | 9.09 | 6.39 | 4.71 | 6.64 |
EV/EBITDA Ratio | 58.58 | 55.77 | 84.67 | 57.03 | 40.76 | 66.18 |
EV/EBIT Ratio | 135.76 | 84.94 | 164.76 | 95.87 | 61.78 | 130.33 |
EV/FCF Ratio | - | - | 154.35 | 36.50 | 127.07 | 77.19 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 4, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Debt / Equity Ratio | 0.03 | - | - | - | - | 0.05 |
Debt / EBITDA Ratio | 0.64 | - | - | - | - | 0.54 |
Debt / FCF Ratio | - | - | - | - | - | 0.63 |
Net Debt / Equity Ratio | -0.15 | -0.25 | -0.44 | -0.44 | -0.32 | -0.31 |
Net Debt / EBITDA Ratio | -3.49 | -2.87 | -8.33 | -5.62 | -3.10 | -3.67 |
Net Debt / FCF Ratio | 0.88 | 1.76 | -15.18 | -3.59 | -9.67 | -4.28 |
Asset Turnover | 0.43 | 0.46 | 0.45 | 0.63 | 0.80 | 0.71 |
Inventory Turnover | 1.69 | 1.98 | 1.79 | 2.23 | 2.95 | 1.96 |
Quick Ratio | 3.10 | 3.70 | 10.23 | 9.93 | 5.56 | 4.58 |
Current Ratio | 4.58 | 5.22 | 12.15 | 11.76 | 6.72 | 5.57 |
Return on Equity (ROE) | -0.36% | 4.13% | 2.71% | 4.60% | 6.22% | 0.22% |
Return on Assets (ROA) | 1.02% | 3.00% | 1.54% | 2.62% | 3.79% | 2.27% |
Return on Invested Capital (ROIC) | -2.46% | 6.75% | 4.01% | 6.74% | 8.95% | 1.44% |
Return on Capital Employed (ROCE) | 1.80% | 5.40% | 2.60% | 4.50% | 6.60% | 4.10% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 4, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Earnings Yield | -0.13% | 0.85% | 0.56% | 0.93% | 1.33% | 0.04% |
FCF Yield | -6.40% | -2.83% | 0.60% | 2.53% | 0.74% | 1.24% |
Dividend Yield | - | - | - | 0.69% | - | - |
Payout Ratio | - | - | 123.24% | - | - | - |
Buyback Yield / Dilution | 0.43% | 0.11% | 0.00% | -0.07% | 0.41% | -0.40% |
Total Shareholder Return | 0.43% | 0.11% | 0.00% | 0.62% | 0.41% | -0.40% |